Impact
At Augie’s Quest, our mission is to find a cure for ALS (Amyotrophic Lateral Sclerosis) and improve the lives of those affected by this devastating disease. Through our relentless pursuit of a cure, we have made significant strides and continue to drive progress in the fight against ALS. Here’s how your support has made a tangible impact.
Accelerating Research: Thanks to generous donations from individuals like you, Augie’s Quest has been able to fund groundbreaking research initiatives. These investments have propelled scientific discoveries, leading to a deeper understanding of ALS and potential therapeutic breakthroughs. By supporting Augie’s Quest, you are directly contributing to the advancement of ALS research and bringing us one step closer to finding a cure.
Empowering Researchers: We believe that collaboration is key to unlocking the mysteries of ALS. That’s why Augie’s Quest actively supports and collaborates with top-tier researchers and institutions around the world. By facilitating partnerships and providing essential resources, we empower scientists and clinicians to accelerate their work, share knowledge, and collaborate on innovative approaches. Together, we are fostering a global network of ALS experts who are dedicated to finding effective treatments and, ultimately, a cure.
Enhancing Patient Care: Augie’s Quest recognizes the importance of improving the lives of individuals living with ALS today. While our ultimate goal is to eradicate the disease, we also strive to enhance patient care and support services. We work closely with healthcare providers, advocacy groups, and ALS clinics to ensure that patients have access to the best care, resources, and support systems available. Your contributions enable us to provide vital assistance and programs that improve the quality of life for those affected by ALS.
Raising Awareness: ALS is a complex and devastating disease that often goes unrecognized. Augie’s Quest is committed to raising public awareness about ALS, its impact on individuals and families, and the urgent need for research funding. Through targeted campaigns, events, and community outreach, we aim to educate and engage people worldwide, fostering a sense of empathy and solidarity. By amplifying the voices of those affected by ALS, we strive to build a movement of support that generates lasting change.
We’ve made huge strides in the fight to cure ALS.
Augie’s Quest to Cure ALS announced a $5.8 million commitment to fund the discovery of new candidate drugs to slow, stop, or even reverse ALS disease progression at the Augie’s Quest Translational Research Center through 2024. These funds will cover science staff compensation, yearly equipment costs, and additional needs at the Augie’s Quest Translational Research Center, a key component of the ALS TDI Drug Discovery Engine.
Special thanks to the Sallaberry Family for helping make this possible.
$2.6 million was granted to ALS TDI in 2021 for the discovery of new drug targets, or intervention points, for the effective treatment of ALS. The discovery of a new drug target for ALS is akin to opening an entirely new avenue for slowing, stopping, or reversing a disease that has, up to now, been largely untreatable. Target discovery is the creative science that is foundational to breakthroughs in drug discovery and development and changing outcomes for people diagnosed with ALS in the future. Generous gifts to Augie’s Quest from the Bodine and Bhusri families, and Liz’s Pal’s made this possible, thank you!
AT-1501” Tegoprubart”, – is one of the most promising ALS treatments in development today. AT-1501 blocks the activation of the CD40L pathway, which has been shown to improve muscle function, slow disease progression, and improve survival in a pre-clinical animal model of ALS. Augie’s Quest funding of ALS TDI’s Drug Discovery Engine was critical in creating AT-1501. The AT-1501 research initiative marks the very first time in history a non-profit organization research project has ever reached this stage of drug development — incredible news that was made possible thanks to generous Augie’s Quest supporters. Read about the positive results in the News section of this website.
“There would be no AT-1501 without Augie and Lynne Nieto and Augie’s Quest”.
Under Augie’s personal oversight and continued leadership, more than $150 million has been raised for ALS research.
David-Alexandre Gros
CEO of Eledon Pharmaceuticals
Augie’s Quest funded Duke to study how the microbiome could affect ALS progression. Led by Richard Bedlack, M.D., Ph.D. , this study could show if microbes in the gastrointestinal tract influence the speed of progression in ALS, and might inform the development of a future probiotic that could make patients more resistant to ALS.
Augie’s Quest enrolled another 98 people with ALS into ALS TDI’s Precision Medicine Program, making it the most comprehensive ALS translational research program in history. Special thanks to the Eddie and Jo Allison Smith Family Foundation their critical role in this funding.
Augie’s Quest helped hone-in on the next most promising drug for ALS. With special contributions from the Augie’s Quest Roski Fund, ALS TDI narrowed a list of 200+ promising small molecule drugs that ALS TDI invented down to 8 small molecule drugs with the most promise to emerge as a lead drug for clinical testing.
“We owe much of our progress and ability to expand this transformative, essential research to Augie’s Quest.”
Fernando Vieira, M.D.
CEO and Chief Scientific Officer, ALS Therapy Development Institute
